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1.INTRODUCTION 
    
      HIV infection has been and remains as an important cause for morbidity and mortality 
throughout the world.(1)  More than 70 million people have been infected with the HIV virus 
and about 35 million people have died of HIV since its discovery.(2) As of June 2016,18.2 
million people who were living with HIV had access to antiretroviral therapy,compared to 
15.8 million in June 2015 and 7.5 million in 2010.(3) The introduction of antiretroviral drugs 
and Highly Active Antiretroviral therapy, has led to a sharp decline in fatalities related to the 
disease and  better  survival resulting in increased life expectancy. It is estimated 
that,expanding ART to all people living with HIV and emphasis on prevention choices can 
help avert  21 million AIDS related deaths and 28 million new infections by 2030.(4)  
HIV/AIDS is a growing global problem, in terms of incidence and mortality. Patients with 
HIV are living much longer with HAART so much so that HIV has now become a part of the 
chronic disease burden, like hypertension or diabetes.(5) However adverse metabolic effects 
like dyslipidemia, increased blood pressure and insulin resistance have been attributed to 
HAART. Therefore the use of HAART rises concerns regarding metabolic disorders and 
cardiovascular risk in HIV infected patients who now present an extended life expectancy.(6)  
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In view of the increased longevity attainable with the current therapy for HIV, quality of life 
of people living with HIV also becomes a significant issue to be considered in this context; it 
becomes an important medical outcome measure and its improvement in all domains becomes 
a targeted goal as part of overall management of HIV.(7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
 
2.AIM OF THE STUDY 
 
To study the profile  of chronic diseases among HIV patients who have been on long term 
antiretroviral therapy in a tertiary care centre in South India. 
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3.OBJECTIVES OF THE STUDY 
 
Primary Objective 
To study the profile of chronic diseases among patients with HIV on long term antiretroviral 
therapy. 
 
Secondary Objectives 
1. To  assess the adequacy of treatment of diabetes, hypertension and dyslipidemia as per 
standard guidelines in the same population. 
2. Assessment of cardiovascular risk in the same population. 
3. Assessment of quality of life in the same population. 
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4.LITERATURE REVIEW 
 
4.1 PATHOPHYSIOLOGY 
     The multiple mechanisms by which PLHIV on HAART become more susceptible for 
development of chronic diseases is via the effect of chronic inflammation produced by the 
virus per se as well as side effect profile of the drugs that constitute Highly Active 
Antiretroviral Therapy(HAART) .Moreover the increased life expectancy offered by HAART 
contributes to the increased incidence of metabolic and cardiovascular diseases. 
HIV and atherosclerosis 
Atherosclerosis is found to occur and progress at a faster rate in patients with HIV infection 
when compared to HIV non infected individuals.(8) 
1. HIV infected individuals have been found to have increased levels of triglycerides and 
decreased levels of HDL cholesterol.(9) 
2. A major role is also played by chemokines  both in the occurrence of HIV infection and     
progression to atherosclerosis due to HIV and genetic variations in them has been  
found to cause the same.(10)Chemokines play a role in both the entry of HIV into the 
cell as well as the ability of monocytes to enter the subendothelial space which is an 
important step in development of atherosclerosis. Mononuclear phagocytes (monocytes 
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and macrophages) are primarily involved in the inflammatory processes in the 
development of atherosclerosis. MCP 1(Monocyte Chemoattractant Protein 1) is a 
chemokine which mediates attraction of circulating monocytes to subendothelial space 
via its receptor CCR2.(8) These monocytes phagocyte lipoprotein and form lipid laden 
foam cells. A mutation which causes overexpression of MCP 1 has been found to be 
associated with higher rates of atherosclerosis.(11).Another molecule is Stromal 
Derived Factor 1(SDF 1) which causes activation of  platelets within the atheromatous 
plaque and enables smooth muscle cell migration into subendothelial 
space.Polymorphisms leading to lower expression of this molecule is associated with 
delayed progression to atherosclerosis.(8) Fractalkine is yet another chemokine which 
is upregulated in inflamed tissues.It serves as a chemoattractant as well as adhesion 
molecule. DNA polymorphisms in the gene for its specific receptor CX3CR1 have been 
implicated in atherosclerosis.(12) 
3. It has also been found that higher CD4 counts relate to slower rates towards 
atherosclerosis and similarly low CD4 counts as a significant risk factor for increased 
subclinical atherosclerosis.(13). 
4. HIV-1 infection is implicated in hampering insulin sensitivity. The HIV-1 accessory 
protein Vpr has been found induce transcription of glucocorticoid-responsive 
promoters, thereby increasing sensitivity to glucocorticoids . It also diminishes 
peroxisome-proliferator-activated receptor-γ (PPAR-γ) activity  and interferes with the 
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inhibitory effects of insulin on forehead transcription factors. Hence, tissue-selective 
insulin resistance is produced.(14) 
HAART and atherosclerosis 
      The role of antiretroviral agents,particularly protease inhibitors in causing dyslipidemia 
has been widely studied.  
     The proposed mechanisms include:(15,16) 
 1. The activation of sterol regulatory element-binding protein-1 (SREBP-1) is inhibited  in the 
liver and adipocytes along with the protease mediated breakdown of apolipoprotein-B. 
 2. Upregulation of very low density lipoproteins (VLDLs) formation. 
 3.Decrease in the lipoprotein lipase activity . 
 4. Altered  mobilization of lipid stores. 
     Antiretroviral therapy other than those containing protease inhibitors have also been found 
to cause lipid disorders.(17) 
   The mechanisms by which ART,especially protease inhibitors cause 
hyperlipidemia,lipodystrophy,central obesity and insulin resistance include: 
1.Inhibition of insulin mediated glucose uptake in adipocytes in a dose dependent manner by 
decreasing the intrinsic transport activity of GLUT4 isoform,which is an insulin regulated 
glucose transporter.(18) 
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2. CRABP 1(Cytoplasmic Retinoic Acid Binding Protein 1) is a protein that binds to retinoic 
acid and presents it to cytochrome P 450 which is the enzyme which converts retinoic acid to 
cis 9 retinoic acid,which in turn is the only ligand for retinoic X receptor(RXR). RXR works 
as a heterodimer with peroxisome-proliferator-activated receptor type gamma (PPAR-γ). 
Ligand binding to RXR or PPAR-γ inhibits adipocyte apoptosis and favours adipocyte 
differentiation and proliferation and PPAR gamma acts preferentially on peripheral fat.(19) 
 
Protease inhibitors can act on all the above said steps as depicted in the figure below. 
 
      Protease inhibitors either directly bind to CRABP 1 or inhibits cytochrome P450 3A which 
causes decrease in the amount of cis 9 retinoic acid .This reduces retinoic X receptor (RXR) 
stimulation thereby causing decreased apoptosis and impaired differentation of peripheral 
adipocytes, with lipid release and/or reduced lipid storage. 
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3.   LDL receptor related protein (LRP) is a hepatic receptor which is crucial for  post-prandial 
chylomicron clearance. LRP is also co-expressed on capillary endothelium with lipoprotein 
lipase (LPL). The LPL-LRP complex allows free fatty acid to enter into fat cells by cleaving 
fatty acids from circulating triglycerides and thereby permits fat storage. Protease-inhibitor 
binding of hepatic and endothelial LRP would result in  increased lipid levels in blood and 
decreased fat storage via  reduced cleavage of fatty acids from circulating triglycerides and 
reduced hepatic uptake of chylomicrons .(20) The resulting hyperlipidemia causes fat 
redistribution to the abdomen  as well as  in the breasts as central adipocytes are metabolically 
more active than peripheral ones,hence central fat accumulation automatically results when 
peripheral fat storage mechanisms are impaired. 
4.   Increased lipid levels by the above mechanisms leads to  insulin resistance by:(21) 
a. interference with post-receptor insulin signalling 
b.  competition between glucose and lipid oxidation pathways in skeletal muscle (Randle's 
cycle) 
c.  Inhibition of glycogen synthase 
 
5.There has been recent progress in elucidating the role played by adipokines in HIV and 
HAART induced atherosclerosis. 
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4.2EPIDEMIOLOGY 
GLOBAL BURDEN 
The worldwide prevalence of cardiovascular risk factors like insulin  
resistance,dyslipidemia and hypertension among people living with HIV and  who  has been 
on HAART  has been found to range from 13-45%.(22,23). In a study conducted in Brazil to 
assess prevalence of dyslipidemia, cardiovascular  risk and metabolic syndrome in a group of 
HIV patients with and without HAART  
 separately,it was found that metabolic syndrome was prevalent in 3% of those on  
HAART and 12% of those not on HAART respectively.Total and HDL cholesterol, 
triglycerides and blood glucose were found to be higher in the HAART pool than among the 
non HAART pool. Cardiovascular risk associated with  HAART is reported to be moderate 
(11%) vs 4% without ART. (24) 
 
 A systematic review published in 2017 revealed a range of  8.4% to 47% rate of metabolic 
syndrome in HIV positive  patients. The same review  showed an average prevalence of  
21.5% in Asia and 30.5% in Africa(25) 
 
 In another study which aimed to look at the cardiovascular risk factors in HIV patients on 
long term HAART,40% of individuals were found to have high levels of total cholesterol.   
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Patients who were on HAART had 8 times risk of developing  hypercholesterolemia as 
compared to those not on HAART with 
 an odds ratio of 8.17.Hypertension occurred twice in the HAART population as compared to 
HAART naïve  population,with a prevalence of 25.6%.Cardiovascular disease risk was 
significantly high in patients treated with HAART for more than 5 years.(26) 
 
INDIAN BURDEN 
 The scenario in India is no less different.  
 In a study conducted in South India ,it was found that a high prevalence of metabolic 
syndrome was observed in patients with HIV (16/60), and was more prevalent in 
 the ART-treated group (13/30; P = 0.028). Similarly, insulin resistance was also  noted to be 
high (24/60), and of these patients, 15 were on ART. Seventy-five 
 percent of patients with metabolic syndrome had insulin resistance. 
  All the patients satisfied at least one component of metabolic syndrome.(27) 
 
The data from another Indian study show that metabolic abnormalities like 
hypercholesterolemia,hypertriglyceridemia,low HDL,hyperinsulinemia and truncal adiposity 
were clustered in HIV infected patients with fat redistribution.(28) 
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     Another Indian study which assessed 70 HIV positive patients  showed that the prevalence 
of metabolic syndrome was 20%. Majority of patients had only one component of metabolic 
syndrome (32.9%). Low HDL was present in 50%, followed by raised triglycerides in 42.9%. 
Waist circumference was not increased in any of the patients. There was no statistically 
significant difference between those on HAART and those not on HAART in distribution of 
risk factors and individual components of metabolic syndrome.(29) 
 
      Another  study in Western India showed that of the 306 patients assessed in the study,the 
prevalence of lipodystrophy was 46.1%, and lipoatrophy was significantly associated with 
Stavudine use. The prevalence of dyslipidemia and fasting hyperglycemia was significantly 
higher in the treatment groups. Proportion of patients  with high-density lipoprotein > or = 60 
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mg/dL was significantly higher in the treatment groups; however, this did not have much 
impact on the total cholesterol to HDL ratio .(30) 
      In a study conducted in our hospital to assess the prevalence of cardiovascular risk factors 
in patients on antiretroviral therapy for a period of 1 year,it was found that the prevalence of 
dyslipidemia was found to be statistically significant when patients on ART were compared 
with ART naive patients.34% of patients on ART were found to have high LDL values as 
compared to 17.2% in ART naïve patients.(31) 
 
 Review of literature for  chronic disease profile among  PLHIV on ART is as follows: 
4.3 DIABETES MELLITUS 
      HIV/AIDS patients frequently present with diabetes and related  metabolic complaints.As 
lifespan on ART increases,and access to therapy improves,HIV related diabetes is expected to 
increase. A higher risk of insulin resistance and diabetes mellitus has been described in HIV-
infected patients on ART compared with HIV uninfected patients. 
      14% ,that is,57 of the 411 males who were HIV infected and  using HAART at the 
baseline visit had prevalent DM compared with 5%,which is 33 of the 711 HIV-seronegative 
men (prevalence ratio = 4.6; 95% confidence interval, 3.0-7.1, adjusted for age and BMI. The 
rate of incident diabetes was found to be  4.7 cases per 100 person years among HIV-infected 
men using  antiretroviral therapy compared with 1.4 cases per 100 person years among HIV-
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uninfected men during the four-year period of observation in the Multicenter AIDS Cohort 
Study.(32) 
 
 
     Yet another multicentre cohort study which assessed the development of new onset 
diabetes with exposure to antiretroviral therapy revealed a diabetes incidence of 5.72 per 1000 
person years of follow up and it increased with cumulative exposure to ART.A remarkable  
finding was that exposure to stavudine had the most significant association for development of 
new onset diabetes.Other drugs which were implicated with risk of new onset diabetes were 
zidovudine and didanosine.Interestingly,exposure to ritonavir and nevirapine were associated 
with reduced risk of developing diabetes.(33) 
 In the Swiss HIV Cohort Study, risk factors for  type 2 diabetes were assessed and the same 
was published in 2007 in Clinical Infectious diseases. 4.4 cases per 1000 person years of 
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follow up was the incidence of diabetes calculated.The risk factors identified for increased 
incidence of diabetes were: 
1. Male gender 
2. Age more than 60 years 
3. Black race 
4. Asian ethnicity 
5. CDC stage C 
6. Obesity 
7. Current treatment with NRTIs, NRTIs with PIs 
Treatment with NNRTis were not found to be associated with development of diabetes.(34) 
      The current recommendations advise to check HbA1c  and/or fasting blood glucose at the 
following timelines in  HIV patients : 
1. baseline 
2. prior to initiating ART 
3. within one to three months after starting a new regimen 
4.  every three to six months thereafter while on ART 
The target HbA1c should be maintained at less than 7% for adequate control.(35) 
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It has also been found that the  HbA1C level may underestimate fasting glucose in HIV-
infected patients. In the Multicenter AIDS Cohort Study where 3000 individuals were 
assessed, at a given fasting glucose level ≥125 mg/dL, the concomitant HbA1C was lower in 
HIV-infected individuals as compared with uninfected individuals. Lower CD4 cell counts and 
HAART use were independently associated with a lower HbA1C level than expected for the 
fasting glucose level.(36) 
Strict screening and monitoring must be ensured to make sure that diabetes is not left 
undetected in the HIV population and once diagnosed,the goal should be to achieve glycemic 
control as per target guidelines so as to minimise the cardiovascular risk and thereby prevent 
further complications. 
 
4.4 SYSTEMIC HYPERTENSION 
 
Hypertension is another leading  lifestyle disease which can act as the “killer disease” in many 
circumstances and it is important to know how HIV positive patients are at increased risk for 
the same. 
In a study conducted in Limbe Regional Hospital HIV treatment center in Cameroon between 
April and June 2013, involving 200 HIV/AIDS patients it was found that the prevalence of 
hypertension was double in HIV patients on HAART as compared to those not on it(38% vs 
19%).(37) 
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In the Multicentre AIDS Cohort Study which was done to look at the impact of HIV infection 
and highly active antiretroviral therapy on systolic and diastolic hypertension,it was found that 
7.3% had systolic hypertension and 8% had diastolic hypertension.Men taking highly active 
antiretroviral therapy (HAART) for less than 2 years had similar rates of systolic hypertension 
to that among HIV negative men (OR, 1.06; 95% CI,0.87–1.30), but was significantly higher 
thereafter,  for 2 to 5 years of HAART and for more than 5 years of HAART.  
 But the converse was not true. Diastolic hypertension was not significantly higher among men 
with prolonged HAART use compared to that among HIV negative controls.(38) 
 
In another study done by the AGEhiV Cohort study group, the prevalence of hypertension was 
48.2% in  HIV infected and 36.4% in HIV-uninfected individuals with an odds ratio of  1.63; 
95% CI, 1.27–2.09; P < .001). Across all ages, the prevalence of hypertension was higher in 
HIV infected patients. Seropositive individuals  received significantly more antihypertensive 
treatment (22.8%) compared with HIV negative individuals (13.9%; P < .001) and had a 
comparable rate of hypertension control.Also, among HIV 1infected individuals, stavudine 
exposure was independently associated with hypertension (OR, 1.54; 95% CI, 1.04–2.30). 
This association was attenuated after additional adjustment for either waist-to-hip ratio (OR, 
1.30; 95% CI, .85–1.96) or hip circumference (OR, 1.40; 95% CI, 0.93–2.11). 
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Hence the study suggested  that changes in distribution of  body fat composition, involving 
both abdominal obesity and stavudine-induced peripheral lipodystrophy, might contribute to 
the higher prevalence of hypertension in HIV infected patients.(39) 
 
 
 
  A systematic review published in 2015 looked at the following aspects in HIV  infected 
individuals pertaining to hypertension. 
1. Severity of HIV vs hypertension 
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2. Duration of HIV vs hypertension 
3. Type of ART vs hypertension 
4. Awareness,treatment and control of hypertension in HIV positive patients. 
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      Among the twelve studies which assessed the relationship between duration of  
      HIV infection and presence of hypertension ,two studies reported positive  
      associations which were statistically significant.The association was found to be 
      more in patients who had HIV for more than 10 years,independent of HAART use  
     or age,indicating that a shorter exposure period may not be enough to demonstrate   
     association with HIV and hypertension.(40) 
     In a study conducted in Poland, 28% of HIV patients  were found to have hypertension and 
there was increased prevalence in all  age ranges: < 40, between 41-60 and > 60 which were 
18%, 43% and 53% respectively. Among the hypertensives, grade I, II and III hypertension 
was observed in 58%, 35% and 7% of patients, respectively.  
      Risk factors found were:  
1. increasing age 
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2. male sex 
3. increased BMI 
4. hypercholesterolemia 
5. low HDL 
6. hypertriglyceridemia 
7.  duration of HIV infection greater than 10 years     (41) 
     
4.5 DYSLIPIDEMIA 
 
      In the same study mentioned above,which included 417 HIV  infected Caucasian adults, 
hypercholesterolemia  was observed in 37% of the study group, suboptimal level of HDL in 
20.5% and increased LDL in 31% of patients.  Hypertriglyceridemia was detected in 52% of 
patients, of which it was more than 150mg/dL in 35%. Mixed hyperlipidaemia (concurrent 
elevated  LDL and TG levels) was diagnosed in 21% of patients. Lipids concentrations were 
similar for both sexes , excluding optimal triglyceride level, which was more often observed in 
females than males (55% vs 45%, p=0.05). 
      Patients on HAART when compared with those not on HAART had higher 
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      levels of total cholesterol (mean 178, IQR 153.5-212.5, p=0.0005) and triglycerides (mean 
121, IQR 85-189, p=0.001).(41)
 
      Elevated triglyceride levels  (OR: 2,83; 95% CI:1,04 – 7,71) was the only lipid 
abnormality associated with HAART and further analysis it was associated with protease 
inhibitor based treatment (OR: 2.56;95% CI: 1,66 – 3,96). There was statistically significant 
association between cigarette smoking and hypercholesterolemia 
(p=0,03),hypertriglyceridemia (p=0,01) and mixed hyperlipidaemia (p=0,04). 
 
     The prevalence of metabolic complications in all HIV-infected patients in the Korea 
HIV/AIDS cohort  study  was as follows. The prevalence of obesity based on BMI was 16.4%, 
obesity based on waist/hip ratio was 19%, that of hyperglycemia was 10.4%, 
hypercholesterolemia 6%, elevated LDL levels  5.5%, and hypertriglyceridemia 32.1% 
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respectively. Among metabolic parameters, median serum total cholesterol (155 [48–297] vs. 
176 [11–364] mg/dL; P < 0.001), HDL-cholesterol (38 [4–137] vs. 45 [10–177] mg/dL; P < 
0.001), and triglycerides (155 [14–636] vs. 202 [18–1,040] mg/dL; P < 0.001) were 
significantly higher in treatment-experienced patients . Also, both hypercholesterolemia (2.7% 
vs. 7.7%; P = 0.008) and hypertriglyceridemia (23.7% vs. 37.2%; P < 0.001) showed a 
statistically significant higher value in patients who received HAART compared with those 
who did not.(42) 
      In a study conducted in Congo,it was found that 11.9% of HIV infected patients had a total 
cholesterol greater than 200 mg/dl versus 7.4% of HIV negative individuals (P=0.019). For 
HDL-cholesterol, 36.40% of HIV-infected patients had a serum fasting ≤ 40 mg/dl versus 
15.70% of HIV negative individuals (P < 0.001). Median fasting total cholesterol was also  
elevated  (140 mg/ dl) in HIV positive patients when compared to those who were not/ 
(133mg/dl) [P=0.015].HIV uninfected patients had a median fasting HDL-cholesterol higher 
(58.5 mg/dl) than HIV-infected patients (49 mg/dl) [P < 0.001]. HIV-infected women were 
more likely to have a higher mean of total cholesterol: 147.70 ± 52.09 mg/dl versus 135.72 ± 
48.23 mg/dl for the HIV-infected men (P = 0.014) and of HDL-cholesterol: 55.80 ± 30.77 
mg/dl as compared to 48.24 ± 28.57mg/dl for the HIV-infected men (P = 0.008). Being HIV 
positive on first-line antiretroviral therapy based on stavudine-lamivudine-nevirapine was 
associated with high prevalence of total cholesterol > 200 mg/dl and HDL-cholesterol ≤ 40 
mg/dl. (43) 
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     In another study conducted in Cameroon it was found that receiving HAART and HIV 
duration of 42 months and more were independently associated with total cholesterol 
≥ 200 mg/dL. Receiving HAART was independently associated with raised LDL-cholesterol 
values.(44)  
     A Brazilian study  showed  low HDL as the most frequent abnormality (53.7% of patients 
had levels < 40 mg/dL), followed by elevated triglyceride levels (36.1% of patients had levels 
> 200 mg/dL) among a sample of  93 HIV patients who were on ART from 2005 to 2006.(45) 
 
  4.6 ISCHAEMIC HEART DISEASE AND STROKE 
 
     The presence of diabetes,hypertension and dyslipidemia invariably contributes to the 
development of vascular diseases. 
    Although the incidence of cardiovascular diseases classically associated with human 
immunodeficiency virus has decreased considerably with antiretroviral therapy, cardiovascular 
risk, and especially ischemic heart disease, are higher in HIV-infected patients than in 
uninfected individuals. This is due to the interaction of patient-dependent factors with virus-
dependent factors, as well as factors associated with antiretroviral therapy. With increasing of 
life expectancy and the chronicity of HIV infection, cardiovascular disease has emerged as an 
important cause of morbidity and mortality in HIV patients. 
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    The largest prospective study of cardiovascular risk with ART is the Data Collection on 
Adverse Events of Anti-HIV Drugs (DAD) study.Of 23 437 participants, 345 (1.5%) 
developed a first MI, an incidence of 3.7 per 1000 person-years. Of these, 29% were fatal, 
representing 10% of all deaths in the study.  
     Incidence of MI increased directly with longer exposure to ART (relative risk 1.16, 95% CI 
1.09 to 1.23, per year of exposure, P<0.0001) for up to 6 to 7 years of exposure.  
     Importantly, this relative association between exposure to ART and increased risk of MI 
was comparable irrespective of age or gender. 
      In further analyses evaluating the impact of individual antiretroviral drug classes, the 
relative risk of protease inhibitor therapy was also 1.16 (95% CI 1.10 to 1.23, P<0.001) 
whereas the annual relative risk for non nucleoside reverse-transcriptase inhibitor–based 
therapy was not significant (relative risk 1.05, 95% CI 0.98 to 1.13).(46) 
      
 A recent large cohort study found a strong and consistent association of HIV with a 50% 
increased risk of MI, independent of traditional risk factors, such as age, race, socioeconomic 
status, and substance abuse .(47) 
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     The findings of the SMART (Strategies for Management of Antiretroviral Therapy) trial 
also suggest that HIV and attendant inflammation are important in conferring risk for 
ischaemic heart disease. (48) 
This is further supported by a recent study, which found that new cycles of HIV replication 
may also play a role in ongoing inflammation in patients with modest antiretroviral therapy  
nonadherence . In HIV-infected patients, studies suggest that immunodeficiency (CD4+ cell 
counts <200 cells/mm
3
) is significantly associated with a higher risk of MI.(49) 
 
4.7 CHRONIC KIDNEY DISEASE 
Even though exact epidemiologic data are missing because of the use of different screening 
techniques, chronic kidney disease in HIV-infected patients is a common and  clinically 
relevant finding. 
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 Proteinuria and elevated creatinine level have been found in 7.2%(50) to 32% (51) of HIV-
seropositive patients and were associated with an increased rate of death in a study of 2038 
female HIV-infected patients  in a study conducted in Durham.(52) 
 
    HAART has been found to reduce progression from AIDS to end-   stage renal disease in 
patients of African descent by 38%, yet a significant increase in the prevalence of end-stage 
renal disease (ESRD) associated with an increase in the prevalence of HIV infection in this 
population has been predicted.(53) 
In a cohort study conducted in Western India to assess nephrotoxicity of Tenofovir, it was 
found that of 1,271 patients started on a Tenofovir containing antiretroviral treatment (ART) 
83 (6.53%) developed renal dysfunction, of which 79 had impaired serum creatinine and five 
had Fanconi’s syndrome. Renal dysfunction was more common with boosted a protease 
inhibitor (PI) (9.44%) based regimen as compared to a non  nucleoside reverse transcriptase 
inhibitors (NNRTI) (5.01%)-based regimen (P = 0.003). The mean decline in creatinine 
clearance from baseline was 22.27 ml/min.(54) 
Recently, the EuroSIDA study reported that only 0.64% of 9044 patients developed advanced 
CKD/ESRD/renal death during a median follow-up of 5.0 years, with an incidence rate of 1.32 
per 1000 personyears follow-up. At 6 years from baseline, 0.83% were estimated to have 
experienced the endpoint overall.(55)  
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Traditional risk factors for CKD are becoming increasingly prevalent in HIV-infected 
populations, including aging, diabetes mellitus, hypertension, cardiovascular disease, previous 
AKI and race/ethnicity (56).  
Risk factors for CKD in HIV-persons are therefore a combination of traditional and HIV-
related factors including low CD4 counts, high viral load, intravenous drug use, HCV co-
infection and also cART, mainly tenofovir, indinavir, lopinavir/ritonavir, atazanavir/ritonavir 
and abacavir.(57) 
 
4.8 OSTEOPOROSIS 
 
Randomized controlled trials comparing bone mineral density in protease inhibitor (PI) vs 
non-PI regimens have shown mixed results, with some studies revealing that PI-containing 
regimens led to decreased spine BMD and others showing no difference in total body or hip 
BMD between treatment groups.(58) (59) 
Randomized trials comparing BMD in tenofovir  and  non tenofovir regimens have 
consistently found that tenofovir is associated with significantly decreased BMD at the hip and 
spine.(60,61) 
During the HAART era, cumulative exposure to tenofovir was associated with an increased 
risk of incident fracture (HR, 1.16; 95% CI, 1.08–1.24; P < .0001)(62)    
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Similar to general population, osteoporosis is an important risk factor for fracture among HIV 
patients  . Among 1006 participants in a cohort study, the presence of osteoporosis was 
associated with a fourfold increased risk of incident fracture (mainly of the rib or sternum, 
hand, foot, and wrist). Prevention of osteoporotic fractures is of utmost importance in this 
population as the longevity is also currently being increased as compared to olden times.(63) 
Another study in Italy showed that  lower femoral Z-score was independently associated with 
factors like  low BMI, AIDS diagnosis, HCV co-infection, antiretroviral treatment, and non 
traumatic bone fractures; a lower lumbar Z-score was associated with age, BMI, CD4 T-cell 
counts, and non traumatic bone fractures. Prevalence of  non traumatic bone fractures was 
27.0%, predictors being male gender, HCV co-infection, and lower femoral Z-scores. The 
results of this study suggest that measuring bone mineral density by DEXA in all HIV patients 
regardless of any further specification may help retrieving one-fifth of patients with early 
osteoporosis not identified using current criteria for selective screening of bone mineral 
density(64). 
A study conducted in Taiwan revealed that mong 320 patients with a median age of 37.3 
years, body mass index (BMI) of 21.4 and 94.4% on ART, osteopenia and osteoporosis were 
diagnosed in 35.6% and 3.8%, respectively. On multivariate linear analysis, factors associated 
with reduced BMD were increasing age (p=0.006), longer duration on antiretroviral therapy 
(p=0.007), and a decreasing BMI (p=0.002). Being underweight with a body mass index 
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(BMI) less than 18.5 was independently associated with reduced BMD (proportional odds 
ratio, 4.12; 95% confidence interval, 1.93-8.82).(65) 
 
4.9 LIPODYSTROPHY 
 
     Lipodystrophy can be either lipoatrophy or lipohypertrophy,both of which can be found in 
individuals taking long term HAART. 
     Exposure to NRTIs-   
Data suggest that exposure to certain NRTIs is the major factor associated with lipoatrophy . 
Trials comparing different antiviral regimens suggest that thymidine analogs (in particular 
stavudine, but also zidovudine) play an important role in pathogenesis of lipoatrophy.(66) 
     Prevalence of lipoatrophy  was found to be increased with the use of stavudine and 
indinavir, and lipoaccumulation was associated with duration of ART in a study conducted 
among 1077 patients visiting HIV Out Patient Study Clinics.(67)  
 
     In a subset of patients participating in an open-label randomized trial comparing tenofovir-
emtricitabine and zidovudine-lamivudine, each in combination with efavirenz, total limb fat, 
as measured by dual energy x-ray absorptiometry (DEXA), was less with zidovudine than 
tenofovir (mean 6.9 versus 8.0 kg fat)(68) 
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 Exposure to other ART classes-  
     Some studies have suggested that although NRTI use contributes to fat wasting, protease 
inhibitors may act synergistically with NRTIs .(69) However, therapy with protease inhibitors 
alone does not appear to lead to lipoatrophy .  
     Similarly, in a metabolic substudy of a trial evaluating various ART regimens (ACTG 
5142), the incidence of lipodystrophy was higher with efavirenz plus two NRTIs compared 
with lopinavir plus two NRTIs or efavirenz plus lopinavir, but the association between 
efavirenz and lipoatrophy was mainly in combination with stavudine  or lamivudine, not 
tenofovir.(70) 
 
4.10 QUALITY OF LIFE ASSESSMENT 
 
     HIV is a disease which not only affects a person physically.but also socially and 
psychologically.Hence evaluation of quality of life becomes important in these patients. 
      A study conducted in Orissa to evaluate the same in a group of  153 patients on 
antiretroviral therapy found that the overall QOL score was moderate(using the WHOQOL 
HIV BREF questionnaire).Also lower BMIs were associated with poorer QOL scores.(71)  
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      Another study done in a tertiary care centre in South India using the same            
questionnaire showed that the overall mean score for quality of life in a scale     of 0 to 20 was 
13.29,lowest individual score being in the social relationship domain. (72) 
 
A study conducted in Xinjiang province in China showed alarming findings of high 
stigmatization: 86% of the patients were afraid to tell others they were HIV positive and 69% 
often felt or always felt depressed. Only 1% of the patients were on antidepressant 
treatment.(73) 
 
An Australian study conducted  detailed interviews which revealed the long standing 
difficulties of living with HIV,particularly in the domains of intimate relationships, perceived 
stigma, and chronic ill health.  
 
The factors related to lower health related quality of life(HRQL) were:  
1. newly diagnosed HIV (p=0.001) 
2. never received anti-retroviral treatment (p=0.009); 
3. depression, unemployment or a high frequency of adverse symptoms, (all p<0.001).  
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Total quality of life was  reduced by perceived stigma with 33%  of surveyed patients 
reporting persistent fears of both disclosing their HIV status and infecting others. 
The analysis showed that psychological distress had a large impact on quality of life in this 
cohort. This was accentuated in people with poor physical health which in turn was associated 
with unemployment and depression. People with HIV infection are living longer and residual 
side effects of the earlier regimens complicate current clinical management and affect their 
quality of life. However, even for the newly diagnosed exposed to less toxic regimens, HIV-
related stigma plays an important role in building  negative social and psychological effects. 
Context-specific interventions are required to address persistent distress related to stigma, 
reframe personal and public perceptions of HIV infection and alleviate its disabling social and 
psychological effects.(74) 
 
4.11 LACUNAE IN CURRENT KNOWLEDGE AND JUSTIFICATION 
Thus there is a need to look at the individual chronic disease profile of HIV patients who have 
been on long term antiretroviral therapy in our hospital and thereby assess their cardiovascular 
risk and adequacy of treatment .The duration of ART in all of the previous Indian studies has 
been less than 5 years.Here we aim to look at the chronic diease profile with respect to a 
longer duration of ART of more than or equal to 5 years.Moreover,the adequacy of treatment 
of these diseases has not been looked at in earlier studies.It will also be useful to look at their 
quality of life so that we can modify our standard of care to improve the same as well. 
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5.MATERIALS AND METHODS 
5.1 STUDY SETTING 
The study was conducted in Christian Medical College, Vellore (CMC), a tertiary  
care  level hospital situated in Vellore, Tamil Nadu. Patients were recruited from  
those attending the General Medicine OPD of  CMC Vellore. 
 
5.2 STUDY DESIGN 
This is a cross sectional study to evaluate the presence of chronic diseases among HIV patients 
on antiretroviral therapy for more than or equal to 5 years. 
HIV positive patients presenting to the out patient department of General Medicine Unit 1 
were recruited as per inclusion and exclusion criteria given below. 
Diagnostic criteria for chronic diseases included in the study are as described in appendix.  
 
5.3 PARTICIPANTS 
 
INCLUSION CRITERIA 
All patients detected to be HIV positive in our hospital and who have received ART for more 
than or equal to 5 years and on follow up with Medicine 1 OPD. 
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EXCLUSION CRITERIA 
Age less than 18 years. 
Patients who have developed any of the chronic diseases of interest prior to initiation of ART. 
 
5.4 SAMPLE SIZE 
As our study aims at assessment of chronic disease profile of HIV patients on long term 
antiretroviral therapy,and not prevalence or incidence of any of the diseases per se,sample size 
calculation based on previous studies was not feasible.Hence it was decided to include in the 
study, all patients satisfying the inclusion criteria who were registered with Medicine 1 OPD 
and who have been on ART for more than or equal to 5 years.The estimated  number of  such 
patients satisfying the inclusion criteria which was obtained based on chart review is 
50.Sample collection was started after Institutional Review Board approval of the same. 
 
5.5 METHOD OF RECRUITMENT 
Institutional Review Board approval and Ethics Committee approval was obtained (IRB Min 
No 10024,  dated 04/04/2016).  
After the approval, patients presenting to the Department of General Medicine, who met the 
inclusion criteria were enrolled in the study via convenient sampling. 
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5.6 FUNDING 
The protocol was approved by the Institutional Review Board and funding was provided by 
the FLUID research grant of IRB. 
 
5.7 METHOD OF EVALUATION  
HIV positive patients presenting to the out patient department of General Medicine Unit 1 
OPD were recruited as per inclusion and exclusion criteria. 
 
The following were undertaken. 
 
1) Informed written consent were taken from all participants by the principal investigator. 
The consent as taken after giving written information regarding nature of the study, verbal 
explanation of the same and clarification of the queries. 
  
2) A questionnaire including demographic details of all study participants, treatment 
details,smoking history, history of alcohol consumption, was administered by the principal 
investigator. 
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3) Quality of life assessment was done using WHOQOL BREF Questionnaire. 
4)  Physical examination including systolic and diastolic blood pressure, height and 
weight,waist circumference was done by the principal investigator. 
5) Blood pressure was taken with a standardized sphygmomanometer. Readings were taken 
with the patient seated on a chair for 15 minutes of rest. Blood pressure reading in mm Hg 
was taken in the right upper limb. 
6) Height was measured using a stadiometer to the nearest 0.1cm. 
7) Weight was measured using a calibrated weighing machine   to the nearest 0.1kg. . BMI will 
be calculated. 
8) Waist circumference  was measured using a stretch resistant tape at the mid- point between 
lower margin of last palpable rib and top of iliac crest to the nearest 0.1cm.  Measurement  
was  taken at the end of normal expiration, with the subject relaxed, standing with feet close 
to each other and arms by side. 
 
5.8 VARIABLES 
Demographic:Age,Sex,Occupation,Level of education,Native state 
Presence of: 
1) Diabetes mellitus 
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2) Hypertension 
3)  Dyslipidemia 
4) Ischemic heart disease 
5) Cerebrovascular disease 
6) Chronic kidney disease 
7) Osteoporosis 
            8) Lipodystrophy 
           9)Date of ART initiation 
           10) Details of ART drugs 
          11) Smoking status,smoking pack years and number of years since quitting    
                smoking if reformed smoker 
         12)Drinking status,duration  and frequency of alcohol intake and quantity of  
               alcohol consumed per day. 
Clinical Examination: 
13)Blood pressure 
14)Height 
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15)Weight 
 16)Body mass index 
 17)Waist circumference 
               
The following tests were done(if  not already been done) in addition to history and clinical 
examination  to evaluate for the above mentioned conditions. 
Fasting and 2 hours post prandial blood sugar   
HbA1c 
Total cholesterol,HDl,LDL and Triglycrides(Fasting) 
Serum creatinine and blood urea 
ECG,Treadmill test (in patients who are symptomatic or have ECG changes) 
DEXA scan-for bone mineral density to define osteoporosis as well as whole body fat analysis 
to define lipodystrophy. 
 
Trunk fat/lower limb fat mass ratio >2.28 identified 54.3% of patients with HIV receiving 
HAART as having lipodystrophy and had the highest odds ratio for predicting metabolic 
syndrome; based on a previous study conducted in our institution which developed an 
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objective definition of HIV associated lipodystrophy using regional fat mass ratios.(75) Hence 
we used trunk fat/lower limb fat mass ratio more than 2.28 as cut off for defining 
lipodystrophy. DEXA for the same was done along with the whole body DEXA which was  
done for assessment of bone mineral density. 
 
The above mentioned chronic diseases are defined as per standard criteria described in 
annexure. 
The presence of each of the diseases were assessed as well as adequacy of treatment of 
diabetes,hypertension and dyslipidemia were assessed based on standard criteria for treatment 
goals as described in annexure. 
For adequacy of control of diabetes, 3 different values of HbA1c were taken at different points 
of time and the average was calculated to assess the adequacy of treatment.If the average 
Hba1c was less than or equal to 7,it was considered as adequate control and if more than 7,it 
was considered not well controlled. 
For adequacy of control of hypertension, 3 different values of  blood pressure recordings were 
taken at different points of time and the average was calculated to assess the adequacy of 
treatment.If the average blood pressure was less than  140/90mmhg, it was considered as 
adequate control and if more than or equal to 140/90mmhg, it was considered not well 
controlled. 
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For adequacy of control of  dyslipidemia, 3 different values of  LDL values were taken at 
different points of time and the average was calculated to assess the adequacy of treatment.If  
the average LDL was less than  100mg/dL  it was considered as adequate control and if more 
than or equal to 100mg/dL , it was considered not well controlled. 
 
Quality of life was assessed based on WHOQOL HIV BREF questionnaire.  It was calculated 
using the WHO QOL HIV BREF  scale which has  six domain scores namely physical, 
psychological, level of independence, social relationships, environmental, and spirituality, 
religion, personal beliefs (SRPB).  
Individual items are rated on a 5-point Likert scale where 1 indicates low, negative 
perceptions and 5 indicates high, positive perceptions. 
 Higher score indicates better QOL. For better result interpretations, the QOL scores between 
4 - 9.9 were taken as low scores, 10 -14.9 as medium scores, and 15 - 20 as high score.(71) 
Scores were calculated using SPSS software version 17. 
 
Cardiovascular risk was calculated based on American Heart Association Guidelines 2013 
Risk Calculator. 
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5.9 STATISTICAL ANALYSIS 
      Data from the clinical research form were entered into the Epidata v 3.1 data entry 
software and then exported to SPSS version 17, IBM Corporation for analysis. All analysis 
was performed by trained biostatistician Mrs Mahasampath Gowri. 
For continuous data , the descriptive statistics Mean, Standard deviation, Median, Minimum 
and Maximum are presented. For categorical data, the number of patients and percentage are 
presented. Based on the normality of data, the parametric t test or nonparametric Mann -
Whitney test were applied to the data. The Chi-square or Fisher exact test was applied to the 
data when required. 
P value less than 0.05 was considered statistically significant. 
 There were mainly 4 different ART drug groups namely : 
T E E/T L E-Tenofovir+Emtricitabine+Efavirenz/Tenofovir+Lamivudine+Efavirenz 
Z L N-Zidovudine+Lamivudine+Nevirapine 
S L N –Stavudine+Lamivudine+ Nevirapine 
T E At Rt- Tenofovir+Emtricitabine+Atazanavir+Ritonavir 
For statistical analysis,TEE and TLE were grouped into one group and ZLN and SLN were 
grouped into one group for comparison.T E At Rt could not be included in P value calculation 
using chi square test in view of very small number of patients (less than 5) included in the 
group. 
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6. RESULTS 
The study was conducted from 1
st
 June 2016 to 1
st
 June 2017. 
 50 patients were recruited in the study as per inclusion criteria. 
6.1 DEMOGRAPHIC VARIABLES 
AGE 
The mean age was 48.46± 8.77,the least being 20 years and the highest being 65 years.  
GENDER 
Males were more in number and constituted 38 out of 50,that is 76% of the total number .  
 
 
Figure 1-Gender distribution 
76% 
24% 
Male Female
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NATIVE STATE 
Majority of patients were from Tamil Nadu,22 out of 50 (44%) and Andhra Pradesh 20 out of 
50(40%).2%  each were from Kerala and Jharkhand. 4% each were from Pondicherry, Bihar 
and Manipur. 
 
 
Figure 2-Place distribution according to native state 
 
LEVEL OF EDUCATION 
 
 Educational qualification wise, most patients belonged to high school and 
44% 
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4% 
2% 
4% 
2% 
4% 
Tamil Nadu Andhra pradesh Pondicherry Kerala Bihar Jharkhand Manipur
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 intermediate or diploma groups.36% constituted intermediate or diploma qualification  
 while 20% constituted high school qualification. 
The percentages of primary school and middle school qualification were 8% and 16% 
respectively.Another 16% had graduate or postgraduate degree, while 4 % had professional 
qualifications. 
 
 
Figure 3-Level of education of study population 
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OCCUPATION 
The distribution of occupation among the patients reflected most patients being in the semi 
professional group,that is 22 % of the total study population.12% were unemployed,10% 
belonged to unskilled group,14%  were semiskilled,18%  each were either skilled  or belonged 
to clerical,shop owner or farmer group.6% had professional jobs. 
 
Figure 4-Distribution of occupation among study population. 
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6.2 ART DRUG GROUPS 
The four main groups of ART drugs into which patients were categorised according to drug 
regimen are as follows: 
T E E/T L E-Tenofovir+Emtricitabine+Efavirenz/Tenofovir+Lamivudine+Efavirenz 
Z L N-Zidovudine+Lamivudine+Nevirapine 
S L N –Stavudine+Lamivudine+ Nevirapine 
T E At Rt- Tenofovir+Emtricitabine+Atazanavir+Ritonavir
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Figure 5-ART drug groups 
 
6.3 CHRONIC DISEASE PROFILE OF STUDY POPULATION 
 
Assessment of chronic disease profile of the recruited sample of patients led to the following 
results: 
DIABETES MELLITUS 
20 among the 50 recruited patients were found to have diabetes based on standard 
guidelines,which constitute 40% of total patients. 
All patients with diabetes were above the age of 40 years. 
 
Figure 6-Distribution of diabetes among study population 
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 59 
 
Comparison of the different ART drug groups with diabetes is shown in Figure 6. 
 
Figure 7-Comparison of ART group with diabetes 
 
12 out of 31 patients in the TEE/TLE group were found to have diabetes, as compared to 4 out 
of 10 in ZLN group and 1 out of 6 in SLN group. Only 3 patients were on Tenofovir  
Emtricitabine  Atazanavir Ritonavir  and all 3 of them were confirmed to have diabetes. 
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Diabetes  TEE/TLE ZLN/SLN T E At Rt Total 
Yes 12(38.71%) 5(31.25%) 3(100%) 20 (40%) 
No 19(61.29%) 11(68.75%) 0(0%) 30(60%) 
Total 31(100%) 16(100%) 3(100%) 50(100%) 
Pearson chi 2=0.2544                                                                                 P=0.614 
There was no statistically significant association between type of ART drug and diabetes in 
the study population. 
 
Table 2-Duration of ART versus diabetes 
Diabetes Number of  patients Mean duration of  ART 95% confidence 
interval 
Yes 20 9.241±3.34 (7.6802-
10.8019) 
No 30 9.538±2.87 (8.4660-
10.6118)     
P value=0.7378 
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Using two sample T test with equal variances, P value of 0.7378 was computed and the mean 
duration of ART was found to be not statistically different in groups who developed diabetes 
and those who did not. 
HYPERTENSION 
Only 13 patients were found to have hypertension among the 50,which constitute 26% of total 
patients. 
All patients with hypertension were above the age of 40 years. 
Comparison of  ART drug groups with hypertension is shown in Figure 7. 
  
Figure 8-Distribution of hypertension among study population 
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Figure 9-Comparison of ART drug group with hypertension 
 
Hypertension was found in 10 out of  31 patients in the TEE/TLE group and 3 out of 7  
in the ZLN group.Neither SLN nor TE At Rt groups had patients with hypertension. 
 
Table 3-Comparison of ART drug group with hypertension 
Hypertension TEE/TLE ZLN/SLN T E At Rt Total 
Yes 10(32.26%) 3(18.75%) 0(0%) 13(26%) 
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Total 31(100%) 16(100%) 3(100%) 50(100%) 
 
Pearson chi 2=0.9624                                                                                          P=0.327 
 
There was no statistically significant association between type of ART drug and hypertension 
among the recruited sample of patients. 
 
 
Table 4-Duration of ART versus hypertension 
 
Hypertension Mean duration of ART 95% confidence interval 
Yes 9.3825±3.14 (7.4866-11.2783) 
No 9.4328±3.04 (8.4178-10.4479) 
P value=0.9596 
Using two sample T test with equal variances,P value of 0.9596 was computed and the mean 
duration of ART was found to be not statistically different in groups who developed 
hypertension and those who did not. 
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DYSLIPIDEMIA 
Dyslipidemia was prevalent in 31 out of 50 patients which amounts to 62% of the total 
number. 
All patients with dyslipidemia were above the age of 40 years. 
 
Figure 10-Distribution of dyslipidemia among study population 
 
The comparison of ART drug group with dyslipidemia is as follows. 
62% 
38% 
DYSLIPIDEMIA PRESENT DYSLIPIDEMIA ABSENT
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Figure 
11-Comparison of ART drug group with dyslipidemia 
22 patients from TEE//TLE group were found to have dyslipidemia out of the total 31 patients 
which constitute 70.97%.Out of the 10 patients in ZLN group,6 had dyslipidemia and 1 out of 
5 patients in SLN group had dyslipidemia. 2 out of 3 (66.67%) patients in T E At Rt group 
also had dyslipidemia. 
 
Table 5-Comparison of ART drug group with dyslipidemia 
Dyslipidemia TEE/TLE ZLN/SLN T E At Rt Total 
Yes 22(70.97%) 7(43.75%) 2(66.67%) 31 
No 9(29.03) 9(56.25) 1(33.33%) 19 
Total 31(100%) 16(100%) 3(100%) 50(100%) 
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Pearson chi2=3.3084                                                                                 P value=0.069 
Although there is no statistically significant association between type of drug group and 
dyslipidemia,the increased number of dyslipidemic patients among the recruited 
sample,especially in the TEE/TLE group and two thirds of patients in the T E At Rt group 
having dyslipidemia, is worth mentioning. 
 
Table 6-Duration of ART versus dyslipidemia 
 
Dyslipidemia Mean duration of ART 95% confidence 
interval 
Yes 9.42±3.33 (8.1987-10.6481) 
No 9.41±2.55 (8.1829-10.6446) 
 
P value=0.9915 
Using two sample T test with equal variances,P value of 0.9915 was computed and the mean 
duration of ART was found to be not statistically different in groups who developed 
hypertension and those who did not. 
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CHRONIC KIDNEY DISEASE 
Only 4 out of 50 patients were found to have chronic kidney disease. 
 
 
Figure 12-Comparison of ART drug group with CKD 
However it is noted that all patients who had CKD belonged to the TEE/TLE group. 
All four patients were above 50 years of age and all were males. 
Two among the four  patients had been on ART for more than 10 years,one had been on ART 
for 8 years and the last patient 5 years. 
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Table 7-Comparison of ART drug group with CKD. 
CKD TEE/TLE ZLN/SLN T E At Rt Total 
Yes 4(12.9%) 0(0%) 0 (0%) 4 (8%) 
No 27(87.1%) 16(100%) 3 (100%) 46 (92%) 
 
Total 
 
31(100%) 
 
16(100%) 
 
3(100%) 
 
50(100%) 
 
Pearson chi2=2.2566                                                                                P value=0.133 
There was no statistically significant association between type of ART drug and chronic 
kidney disease among the recruited sample of patients. 
 
Table 8-Duration of ART versus CKD 
CKD  Mean duration of ART 95% confidence interval 
Yes 8.55±2.38 (4.7587-12.3332) 
No 9.50±3.10 (8.5761-10.4153) 
P value=0.5540 
Using two sample T test with equal variances,P value of 0.5540 was computed and the mean 
duration of ART was found to be not statistically different in groups who developed chronic 
kidney disease and those who did not. 
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ISCHEMIC HEART DISEASE 
 
 
Table 9-Characteristics of patients with IHD in the study population 
 
AGE ART 
GROUP 
DURATION 
OF ART 
OTHER COMORBID ILLNESSES SMOKING 
STATUS 
54 ZLN >10 years Dyslipidemia Never smoker 
65 TEE 5-10 years Diabetes, Hypertension, Dyslipidemia Former smoker 
54 TLE 5-10 years Diabetes, Hypertension, Dyslipidemia Former smoker 
53 TEE 5-10 years Hypertension, Dyslipidemia,CKD Former smoker 
48 ZLN >10 years Diabetes,Hypertension,Dyslipidemia Never smoker 
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Figure 13-Comparison of ART group with IHD 
 
 
5 out of the 50 patients were found to have ischemic heart disease, of  which 3 were in 
TEE/TLE group and 2 were in the ZLN group. 
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Table 10- Comparison of ART group with IHD 
 
IHD TEE/TLE ZLN/SLN T E At Rt Total 
Yes 3(9.68%) 2(12.5%) 0(0%) 5 (10%) 
No  28(90.32%) 14(87.5%) 3 (100%) 45 (90%) 
Total 31(100%) 16(100%) 3(100%) 50(100%) 
 
Pearson chi2=0.0884                                                                                P value= 0.766 
 
There was no statistically significant association between type of ART drug and ischemic 
heart disease among the recruited sample of patients. 
Table 11-Duration of ART versus IHD 
IHD Mean duration of ART 95% confidence intervals 
Yes 9.09±4.55 (3.4405-14.7297) 
No 9.46±2.89 (8.5874-10.3264) 
P value=0.7981 
Using two sample T test with equal variances,P value of 0.7981 was computed and the mean 
duration of ART was found to be not statistically different in groups who developed ischemic 
heart disease and those who did not. 
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OSTEOPOROSIS 
Table 12-Characteristics of patients with osteoporosis in the study population 
 
PATIENT AGE GENDER ART GROUP DURATION OF ART 
1 52 Female SLN >10  years 
2 40 Female TEE >10  years 
3 49 Male ZLN 5-10 years 
4 54 Male ZLN 5-10 years 
5 52 Male TLE >10 years 
6 44 Male TEE >10 years 
7 54 Male TEE >10 years 
8 56 Male TEE >10 years 
9 63 Female TEE 5-10 years 
10 39 Female SLN >10 years 
11 62 Male TEE 5-10 years 
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Figure 14-Comparison of ART group with osteoporosis  
 
11 out of the 50 patients were found to have osteoporosis,which amounts to 23.4%. 
7 belonged to TEE/TLE group, 2 belonged to ZLN group and 2 belonged to SLN group. 
Among these 11 patients,7 were males and 4 were females.7 patients had received ART for 
more than 10 years while 4 had received ART for 5 to 10 years. 
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Table 13-Comparison of ART group with osteoporosis 
Osteoporosis TEE/TLE ZLN/SLN T E At Rt Total 
Yes 7(22.58%) 4(25%) 0(0%) 11(22%) 
No 24_77.42%) 12(75%) 3(100%) 39(78%) 
Total 31(100%) 16(100%) 3(100%) 50(100%) 
 
Pearson chi2= 0.0345                                                                                P value=0.853 
 
There was no statistically significant association between type of ART drug and osteoporosis 
among the recruited sample of patients. 
 
Table 14-Duration of ART versus osteoporosis 
Osteoporosis Mean duration of ART 95% confidence intervals 
Yes 10.82±3.23 (8.6496-12.9897) 
No 9.02±2.90 (8.0844-9.9653) 
P value=0.0833 
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Using two sample T test with equal variances,   P value of 0.0833 was computed and the mean 
duration of ART was found to be not statistically different in groups who developed 
osteoporosis and those who did not. 
METABOLIC SYNDROME 
 
Figure 15-Comparison of ART drug group with metabolic syndrome 
 
24 out of the 50 patients were found to satisfy the criteria for metabolic syndrome as per 
standard guidelines which amounts to 48% of the total patients. 
Table 15- Comparison of ART drug group with metabolic syndrome 
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Metabolic 
syndrome 
TEE/TLE ZLN/SLN T E At Rt Total 
Yes 13(41.94%) 9(56.25%) 2(66.67%) 24(48%) 
No 18(58.06%) 7(43.75) 1(33.33%) 26(52%) 
Total 31(100%) 16(100%) 3(100%) 50(100%) 
Pearson chi2=0.8685                                                                                 P value=0.351 
 
A large proportion(48%) of the patients were found to be diagnosed with metabolic syndrome 
which was distributed among all the ART drug groups. 
Table 16-Duration of ART versus metabolic syndrome 
Metabolic syndrome Mean duration of ART 95% confidence intervals 
Yes 9.050±2.66 (7.9280-10.1724) 
No 9.760±3.36 (8.4017-11.1200) 
P value=0.4140 
Using two sample T test with equal variances,P value of 0.4140 was computed and the mean 
duration of ART was found to be not statistically different in groups who developed metabolic 
syndrome and those who did not. 
In our study it was also found that none of the patients had evidence of lipodystrophy or stroke 
as per the criteria used(described in annexure). 
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6.4  ASSESSMENT OF THE ADEQUACY OF TREATMENT  
 
ADEQUACY OF DIABETIC CONTROL 
 
3 different values of HbA1c were taken at different points of time and the average was 
calculated to assess the adequacy of treatment.If the average Hba1c was less than or equal to 
7,it was considered as adequate control and if more than 7,it was considered not well 
controlled. 
11 out of the 20 patients were found have adequate control for diabetes which constituted 55% 
of the diabetics in the population. 
 
Figure 16-Adequacy of control of diabetes 
55% 
45% 
Hba1c</=7 Hba1c>7
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ADEQUACY OF CONTROL OF HYPERTENSION 
3 different blood pressure recordings at different points of time were taken and the average of 
the 3 values were calculated.If the average value was less than  140/90mmhg it was considered 
adequately controlled and if more than or equal to 140/90mmhg it was considered not well 
controlled. 
9 out of the 13 patients who were found to have hypertension were found to be adequately 
controlled and 4 of them were not adequately controlled. 
 
  
Figure 17-Adequacy of control of hypertension 
 
59% 
41% 
BP<140/90mmhg BP>/=140/90mmhg
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ADEQUACY OF CONTROL OF DYSLIPIDEMIA 
3 different LDL values at different points of time were taken and the average of the 3 values 
were calculated.If the average value was less than 100mg/dL it was considered adequately 
controlled and if more than or equal to 100mg/dL it was considered not well controlled. 
Only 12 out of the 31 patients with dyslipidemia were found to have LDL<100 and hence was 
considered adequately controlled.19 patients had LDL levels above or equal to 100 indicating 
lack of adequate control. 
 
Figure 18-Adequacy of control of dyslipidemia 
 
 
39% 
61% 
LDL<100mg/dL LDL>/=100mg/dL
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6.4  ASSESSMENT OF CARDIOVASCULAR RISK  
 
Cardiovascular risk was calculated using American Heart Association Guidelines-2013 
calculator. 
41 patients were assessed for cardiovascular risk.The remainder 9 patients could not be 
included as their ages were less than 40 years and the minimum age required for using the 
calculator is 40 years. 
The mean cardiovascular risk obtained was 10.37 ± 8.32. 
When cardiovascular risk was compared with ART drug groups,the results obtained were: 
 
ART drug group Mean cardiovascular risk 
(%) 
Number of patients in each 
drug group 
TEE/TLE 12.57±9.02 26 
ZLN/SLN 6.23±5.48 12 
T E At Rt 7.8%±5.27 3 
P value=0.03138 
Patients in TEE/TLE group had an average cardiovascular risk of 12.57±9.02 % which was 
found to be statistically significant as well.The fact that there is statistically significant 
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increase of cardiovascular risk in this group and that the adequacy of control of dyslipidemia 
is only 39% for the overall study population is unfortunate and indicates the need of 
aggressive control of  cardiovascular risk factors. 
6.5 ASSESSMENT OF QUALITY OF LIFE INDEX  
The mean total QOL was found to be 75.91± 12.3. 
Individual mean domain scores were as follows. 
 
Table 17-Individual mean domain scores of QOL 
Domain Mean score 
Physical 12.36±2.76 
Psychological 13.01±2.31 
Level of independence 13.72±2.36 
Social relationships 12.14±2.68 
Environmental 12.32±2.09 
Spirituality,religion,personal 
beliefs(SRPB) 
12.36±3.12 
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Table 18-Comparison of ART drug group with QOL 
 
 TEE/TLE ZLN/SLN T E At Rt 
Total mean QOL 73.76±11.56 81.02±13.55 70.8±3.13 
P value= 0.06084 
There was no statistically significant association between type of ART drug and quality of life. 
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There were a few limitations of our study which may have impacted the final result. Great care 
was adopted to limit the possibility of errors in this study.  
 
 
1.There was no method of distinguishing between whether the direct effect of HIV and 
HAART led to the metabolic derangements versus the genetic and environmental factors 
which are already at play which could have influenced the development of  the same.Our 
study however was not designed to account for the same. 
 
2.The relatively small  size of sample recruited could also be considered as one of the 
limitations.Further studies employing greater numbers are required to elicit a statistically 
significant association between type of ART drug as well as duration of ART with the 
development of  the diseases of interest. 
3. Since our study also included use of questionnaire, recall bias and interviewer’s bias could 
not be avoided 
 
 
7. LIMITATIONS  
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8.DISCUSSION 
Our study primarily aimed at assessing chronic disease profile in HIV patients on long term 
ART(ART more than or equal to 5 years). 
20 among the 50 recruited patients were found to have diabetes based on standard 
guidelines,which constitute 40% of total patients which is higher than what has actually been 
observed in Western and Indian literature.The type of ART drug group or the duration of ART 
did not influence development of diabetes in our study although previous studies have shown 
stavudine as well as zidovudine to be associated with higher risk for development of diabetes. 
Only 13 patients were found to have hypertension among the 50,which constitute 26% of total 
patients.The prevalence has been found to range from 7.3% to 48.2% across various 
studies.Here also there was no statistically significant association between type of ART drug 
or duration of ART in development of hypertension. 
A significant proportion of patients were found to have dyslipidemia which constitute 61% of 
the total number . A previous study done by Carey et al from our hospital showed statistically 
significant increased prevalence of dyslipidemia in PLHIV on ART for more than or equal to 
1 year as compared to ART naïve patients. 34% of patients on ART were found to have high 
LDL values as compared to 17.2% in ART naïve patients in the study.In our study which had 
considered a longer duration of ART(more than or equal to 5 years),the rate of dyslipidemia 
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was also notably higher(34% versus 61%).The mean age of patients in the study mentioned 
was 39.20 years while that in our study was 48.42 years.The higher age may also have 
influenced  the rate of  dyslipidemia in our study.(31) 
Chronic kidney disease was found in only 4 out of 50 patients,which constitue 8% of the total 
patients.All four were males and all had age above 50 years.Two of them had received ART 
for more than 10 years.Literature shows prevalences of chronic kidney disease ranging from 
7.2% to 32%. Ischemic heart disease was found in 5 out of 50 patients.All 5 patients were 
found to have dyslipidemia, of which 3 of them had all three risk factors:diabetes,hypertension 
and dyslipidemia.Two of them were non smokers and the remainder 3 were reformed smokers. 
Osteoporosis was found in 11 out of 50 patients which accounts for 23.4% of the total number 
which was noted to be higher than values quoted in literature.63.6%  patients who had 
osteoporosis were males.63.6% had also received a longer duration of ART(more than 10 
years). 
24 out of the 50 patients were found to satisfy the criteria for metabolic syndrome as per 
standard guidelines which amounts to 48% of the total patients. This number throws light at 
the fact that metabolic abnormalities are at play in patients with HIV who are on ART and 
adequate measures must be taken for screening,early diagnosis and treatment as well as 
prevention of the same in this population. 
 
 86 
 
 In our sample of patients we were unable to find patients who satisfied the criteria for 
lipodystrophy using Dual energy X ray Absorptiometry,which had a cut off of 2.28 for trunk 
fat by lower limb fat mass ratio.Any value more than on equal to 2.28 was considered 
significant,however none of the patients satisfied the criteria. 
Nor were we able to find any patients with a history of or current evidence of cerebrovascular 
accident in our sample of patients. 
 
With respect to secondary objectives,adequacy of treatment of diabetes,hypertension and 
dyslipidemia was assessed and it was found that 55% of patients with diabetes were 
adequately controlled .Among hypertensives,59% had adequate control 
.Unfortunately,although we had majority of the patients diagnosed with dyslipidemia,the 
control of the same among the patients was not satisfactory in terms of the fact that only 39% 
were having adequate control . 
 
The assessment of cardiovascular risk in the same population showed a higher risk of  
12.57±9.02% in the TEE/TLE group which was found to be statistically significant.The 
overall mean cardiovascular risk was 10.37±8.32. The fact that there is statistically significant 
increase of cardiovascular risk in this group and that the adequacy of control of dyslipidemia 
is only 39% for the overall study population is unfortunate and indicates the need of 
aggressive control of  cardiovascular risk factors. 
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With regards to quality of life, the mean total QOL was  found to be 75.91±12.3 . 
The individual  domain scores namely physical, psychological, level of independence, social 
relationships, environmental, and spirituality, religion, personal beliefs (SRPB) were 
uniformly found to have moderate scores.The lowest individual score was for the social 
relationships domain. 
This is comparable with two recent studies conducted in India which was done to assess 
quality of life in PLHIV.(71,72) 
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9. CONCLUSIONS 
 
1.Assessment of chronic disease profile in our population of PLHIV who had been on ART for 
more than or equal to 5 years revealed high rates of dyslipidemia(62%) followed by that of 
diabetes(40%).Moreover,the proportion of patients who satisfied the criteria for metabolic 
syndrome was also as high as 48% in the same population. 
Such high rates point towards the fact that it is important to anticipate higher rates of 
metabolic abnormalities in this population thereby preparing ourselves for early screening and 
detection of the same so as to prevent complications. 
Another point to note is the increased rate of osteoporosis(23.4%) in the same population 
which necessitates age appropriate early screening for the same so as to prevent fractures. 
2. There was an increased rate of cardiovascular risk in the same population   which was found 
to be significantly high in Tenofovir- Emtricitabine/Lamivudine-Efavirenz   regimens which 
are unfortunately the first line agents of antiretroviral therapy used in our setting. This again 
calls for aggressive control of cardiovascular risk factors after early screening and detection of 
the same. 
3. The adequacy of control of the diseases of interest as per standard  guidelines ,mainly 
diabetes, hypertension and dyslipidemia was also not satisfactory in this population. Control of 
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dyslipidemia was found to be least satisfactory among the three diseases of interest. We 
should target at aggressive control of each of the diseases as soon as they are detected so as to 
mitigate cardiovascular risk. 
4. The quality of life assessed in the same population showed a moderate quality of life 
index,the lowest individual score being that of social relationships.  
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11.ANNEXURES 
ANNEXURE 1-CLINICAL RESEARCH FORM                                                          
SERIAL NO.                                                              CONTACT NO.  
 
SOCIO-DEMOGRAPHIC  DETAILS: 
NAME                                                       AGE                                      
HOSPITAL  NO.   
 
Gender: 1) Male                    2) Female  
 
ADDRESS: 
 
EDUCATION  : 1) Illiterate  2)Primary school  3)Middle school  4)High school  
5)Intermediate or Post-high  school diploma   6)Graduate or post graduate  7)Profession or 
honours 
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OCCUPATION: 1) Unemployed   2) Unskilled   3) Semiskilled   4) Skilled   5) Clerical, shop 
owner, farmer 6) Semi – profession 7) Profession 
 
TREATMENT DETAILS: 
Date of initiation of ART: 
Details of drugs in ART: 
 
PAST HISTORY OF OR TREATMENT FOR : 
1) Diabetes                                            1) YES   2) NO 
2) Hypertension                                    1) YES   2) NO 
3) Dyslipidemia                                     1) YES   2) NO 
4) Chronic kidney disease                      1)YES  2)NO 
5)Ischaemic heart disease                       1)YES  2)NO 
6)Stroke                                                  1)YES  2)NO 
7)Osteoporosis                                        1)YES  2)NO  
8)Symptomatic carotid artery disease     1)YES 2)NO 
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9)Peripheral occlusive vascular disease   1)YES  2)NO 
10)Abdominal aortic aneurysm                 1)YES  2)NO 
If yes date of diagnosis of each of the above to be mentioned.       
 
FAMILY HISTORY OF : 
Diabetes                                           1) YES  2)NO 
Hypertension                                    1)YES 2)NO 
Dyslipidemia                                      1)YES   2)NO 
Ischaemic heart disease                   1)YES   2)NO 
Stroke                                                 1)YES    2)NO 
 
SMOKING: 
a) What is your smoking status?  1)Never smoker  2)Past smoker   3)Current smoker 
 
b) If   2) or 3) of a, smoking pack years?  1)< 10        2)>= 10 
 
c) If   2) of a, number of years since quitting smoking? 1)<20  2)>= 20 
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ALCOHOL : 
a) What is your drinking status?  1)Lifetime abstainer  2)Non-current  drinker  3)Current 
drinker 
 
b) For how many years have you been drinking?  
 
c)  If 2) or 3) of a, how often do you drink per week?   1) Once a week    2) 2 – 6 days a 
week     3)Daily 
 
 
d) If 2) or 3) of a, alcohol consumed in grams per drinking day?  1) <= 30g     2)>= 30g 
 
CLINICAL EXAMINATION: 
1) Blood pressure systolic ( mmHg) : 
2) Blood pressure diastolic(mmHg) : 
 
3) Waist circumference :                                    
 1) Central obesity present    2)No central obesity  
  1:  >= 90cm(men), >=80cm (women) 
  2:   < 90cm (men),   <80cm (women) 
 
4) Height (cm) : 
 
5) Weight( kg): 
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6) Body Mass Index( kg/m2) :      
     
             1.   Underweight: BMI <18.5Kg/M² 
2. Normal: BMI 18.5 to 22.9Kg/M² 
3. Overweight: BMI 23 to 24.9Kg/M² 
4. Obese class I: BMI 25 to 29.9Kg/M² 
5. Obese class II:BMI ≥ 30Kg/M 
 
 
 
INVESTIGATIONS 
FBS 
PPBS 
HBA1C 
FASTING LIPID PROFILE 
CREATININE 
UREA 
ECG 
DEXA SCORE  1)Osteoporosis present.  2)Osteoporosis absent 
Trunk fat to lower limb fat mass ratio 
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 1)More than or equal to 2.28-Lipodystrophy present 
  2) Less than 2.28-No lipodystrophy 
 
SERIAL INVESTIGATIONS FOR ASSESSING ADEQUACY OF TREATMENT 
INVESTIGATION 
 
 
DATE DATE DATE DATE DATE DATE DATE 
HBA1C        
BP RECORDING        
FASTING LDL        
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ANNEXURE 2- WHO QOL HIV BREF QUESTIONNAIRE 
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ANNEXURE 3 - CONSENT FORM 
                    Informed Consent form to participate in a research study  
Study Title:  Chronic disease profile of PLHIV on long term ART 
Study Number: ____________  
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________  
Date of Birth / Age: ___________________________  
(Subject)  
(i) I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions. [ ]  
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being affected. 
[ ]  
(iii) I understand that, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any further 
research that may be conducted in relation to it, even if I withdraw from the trial. I agree to 
this access. However, I understand that my identity will not be revealed in any information 
released to third parties or published. [ ]  
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(iv) I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s). [ ]  
(v) I agree to take part in the above study. [ ]  
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______  
Signatory’s Name: _________________________________ Signature:  
Or  
Representative: _________________  
Date: _____/_____/______  
Signatory’s Name: _________________________________  
Signature of the Investigator: ________________________  
Date: _____/_____/______  
Study Investigator’s Name: _________________________  
Signature or thumb impression of the Witness: ___________________________  
Date: _____/_____/_______      Name and address of the witness _____________ 
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Title of research project :To study the chronic disease profile of HIV patients on long term 
antiretroviral therapy.  
IRB protocol number:  
Dr. Sumayya Abdul Kalam is conducting a study on patients presenting to Medicine 1 OPD 
who are on long term antiretroviral therapy(more than or equal to 5 years).We would like to 
invite you to be a part of this study.  
This form describes what this study is about and how it will be carried out. Signing this form 
will mean that you have agreed to take part. Please read this form carefully and clarify any 
doubt that you may have regarding the study. Feel free to discuss this with your family or 
friends. Your participation in this study is a voluntary act and you are free to refuse 
participation. Your refusal to participate in this study will in no way affect your ongoing 
medical care and treatment in CMCH.  
Purpose of this study:  
This study is being carried out to study thepresence of chronic diseases like 
diabetes,hypertension,high blood cholesterol,chronic kidney 
disease,heartdisease,stroke,osteoporosis on patients who have been on long term antiretroviral 
therapy. By doing so, we will be able to have early detection of such diseases which will help 
us in early intervention,treatment and prevention of complications. We will also be measuring 
ANNEXURE 4- PATIENT INFORMATION SHEET  
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the quality of life in the same population which will enable us to improve our standards of 
care.  
By agreeing to take part, what will you have to do?  
On agreeing to participate, you will be asked a few questions regarding your ART treatment, 
habits, and comorbidities.You will undergo a physical examination including blood pressure, 
height, weight, waist circumference. Relevant blood investigations will be sent. ECG will be 
done for all patients.Bone mineral density scan will be done for all patients.You will have to 
fill a questionnaire which will help in measuring your quality of life.  
Potential risks and discomforts:  
This study does not involve any new drug or treatment.  
There are no other potential discomforts from this study.  
Potential benefits:  
By participating in this study you will help us tohave early detection of such diseases which 
will help us in early intervention,treatment and prevention of complications. We will also be 
measuring the quality of life in the same population which will enable us to improve our 
standards of care.  
Voluntary participation and withdrawal:  
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Participation in this study is entirely voluntary and you may choose not to participate. Doing 
so will not affect your medical care in CMCH in any way.  
Study related injury  
We do not expect any injury to happen to you while participating in this study.  
Payment for the study  
All your investigations will be done at the standard costs prevailing in our institution at the 
time of conducting the study.  
Confidentiality  
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes will be 
reviewed by people associated with the study, without your additional permission, should you 
decide to participate in this study.  
Legal rights  
You are not waiving any of your legal rights by participating in this study or by signing this 
consent form, for example, the right to seek damages under law for any research related injury.  
If you have further queries, kindly feel free to contact Dr. Sumayya Abdul Kalam  
(Phone no 9003805715)-Medicine 1 department. 
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ANNEXURE 5- INSTITUTIONAL REVIEW BOARD APPROVAL 
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ANNEXURE 6 - STROBE CHECKLIST 
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ANNEXURE 7- DATA SET 
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quitsmoke alcohol drinkyears drinkweek drinkday sysbp diasbp waist ht wt bmi fbs ppbs hba1c tc triy hdl ldl creat urea ecg dexa fatmass hba1cd1 hba1cd2 hba1cd3
1 2 20 1 1 110 70 85 158 58 23.23 95 73 4.9 189 201 44 118 0.85 26 1 2 2
1 130 80 87 162 70 26.67 138 181 8 174 215 31 105 0.98 20 1 2 2 7.9 8 8
1 2 17 1 1 110 70 86 164 55 20.45 92 130 5.7 165 136 46 101 0.75 26 1 2 2 5.2 5.7
1 130 84 93 145 62 29.49 105 104 5.8 192 102 42 143 0.62 24 1 2 2
1 2 15 1 1 120 70 83 174 76 25.1 119 98 7 174 268 45 108 1.36 22 1 2 2 7
3 20 1 1 130 80 89 170 74 25.61 181 299 8 135 56 56 78 0.79 20 1 2 2 7.7 9.9 8
3 1 1 140 80 92 159 67 26.5 117 156 5.8 193 118 47 138 0.93 25 1 1 2 6.8 6 5.8
1 2 20 1 1 120 70 85 178 80 25.25 95 132 5.9 199 121 37 130 0.85 23 1 2 2 5.8 5.9
1 110 70 82 158 60 24.03 92 84 5.2 116 70 26 88 0.88 30 1 2 2
1 90 60 65 148 42 19.17 84 120 5.1 111 210 23 60 0.28 30 1 1 2
1 110 70 70 148 45 20.54 96 106 5 195 203 38 143 0.51 15 1 2 2
1 100 70 85 150 63 28 91 130 5.7 160 217 46 98 0.7 29 1 1 2
1 138 84 86 165 64 23.51 81 120 6 224 420 30 148 0.85 26 1 1 2
1 2 5 1 1 140 70 88 163 62 23.34 88 103 5 165 165 32 108 0.71 20 1 2 2
1 3 20 2 2 130 70 84 178 75 23.67 104 132 6.7 125 120 31 98 0.79 14 1 2 2 7.1 6.8 6.7
1 140 90 88 178 75 23.67 141 220 6.9 178 210 36 120 0.73 20 1 2 2 6.6 7.5 6.9
2 1 128 86 92 165 61 22.41 212 299 6.4 180 297 40 68 0.71 25 1 2 2 6 7 6.4
1 1 150 90 95 160 83 32.42 128 142 6.7 185 122 43 131 0.85 24 1 1 2 8.6 7 6.7
1 2 10 1 1 140 86 94 170 87 30.1 84 140 5.5 228 126 63 139 0.86 20 1 2 2
1 120 80 82 150 63 28 102 144 5.1 182 128 62 115 0.5 21 1 2 2
1 130 70 86 158 65 26.04 139 162 6.6 178 119 45 103 0.76 27 1 2 2 7 7.2 7
2 2 30 1 1 130 80 82 165 60 22.04 397 607 9.8 163 134 46 89 1.53 34 1 2 2 7.4 8.9 9.8
1 120 80 95 165 74 27.18 89 107 4.5 177 95 41 112 0.5 20 1 2 2
1 2 30 1 1 110 70 86 161 60 23.15 118 133 6.2 149 240 38 77 1.07 26 2 2 2 6.8 6.7 6.2
1 120 70 89 150 60 26.67 96 134 5.6 195 80 55 111 0.56 18 1 1 2
2 15 1 1 130 90 87 165 67 24.61 100 128 5.5 156 129 48 98 0.71 20 1 2 2
1 2 20 1 1 130 70 92 165 85 31.22 93 98 5.1 135 97 34 83 0.7 20 1 2 2
1 1 120 76 85 163 62 23.34 152 238 7 186 79 50 121 0.73 20 1 2 2 8 7.2 7
1 1 130 80 92 169 81 28.36 120 130 5.3 144 224 31 89 0.75 22 1 2 2
1 120 70 83 157 57 23.12 100 121 5 112 126 37 74 0.86 21 1 1 2
1 110 80 93 150 65 28.89 92 100 5.5 184 131 45 107 0.9 16 1 2 2
1 2 15 1 1 130 70 86 175 75 24.49 112 134 5.4 198 341 30 121 0.88 24 1 2 2
1 1 120 70 96 155 77 32.05 123 148 5.9 122 117 26 85 0.78 22 2 1 2 6.7 5.6 5.9
1 2 25 1 1 130 84 92 157 62 25.15 110 140 6.2 163 103 56 101 0.51 20 1 1 2 7.3 6.5 6.2
1 120 70 85 170 66 22.84 95 142 6.2 126 91 23 77 0.77 18 1 2 2
1 1 140 80 90 160 68 26.56 97 140 5.8 158 170 38 100 0.58 20 1 1 2
1 130 90 83 160 54 21.09 163 228 6.6 176 136 52 118 0.85 24 1 2 2 7.4 6.9 6.6
3 20 1 1 130 84 88 175 64 20.9 98 263 7.7 150 244 37 91 0.92 26 1 2 2 7.5 7.3 7.7
1 1 140 90 91 169 71 24.86 100 106 5.4 201 225 41 131 1.37 20 1 2 2
1 120 70 79 151 55 24.12 103 118 5 177 57 49 117 0.53 20 1 2 2
1 160 90 93 165 83 30.49 100 126 6 136 89 32 91 5.39 40 1 2 2
1 1 130 90 87 168 64 22.68 96 107 5.2 138 139 40 90 1.05 15 1 2 2
1 1 25 1 1 110 70 84 173 83 27.73 94 160 6 279 138 37 217 0.83 23 1 2 2
1 120 80 94 157 57 23.12 90 132 5.8 150 130 44 90 0.62 20 1 2 2
1 1 110 80 92 180 90 27.78 106 124 5.3 143 557 24 57 0.81 25 1 2 2
1 140 80 91 165 68 24.98 204 222 6.8 146 172 48 77 1.39 26 1 2 2 9.4 8 6.8
1 120 90 88 154 59 24.88 105 156 6 182 105 63 111 0.76 24 1 1 2 7 6.2 6
1 130 90 95 170 90 31.14 205 323 8.5 241 305 41 152 0.71 14 2 2 2 7 8 8.5
1 140 80 94 164 88 32.72 110 180 8 175 75 56 99 1.35 26 1 2 2 6.2 6 8
1 2 30 1 1 130 84 95 169 87 30.46 159 303 7.1 166 91 46 99 0.65 24 1 2 2 7 7.6 7.1
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fbsd1 fbsd2 fbsd3 ppbsd1 ppbsd2 ppbsd3 sysbpd1 diasbpd1 sysbpd2 diasbpd2 sysbpd3 diasbpd3 ldld1 ldld2 ldld3 cardrisk quallife
127 124 133 4.1
120 132 138 163 161 181 143 105 90 10
100 92 140 130 120 80 110 80 92 101
1.3
119 98 120 70 3.5
136 189 181 315 242 299 78 3.1
93 98 117 110 163 156 120 80 126 84 140 80 121 120 138 12.9
92 95 128 132 120 80 120 70 148 130 11.5
1
120 130 148 10.3
7.4
107 112 104 192 160 132 120 70 130 80 130 70 117 108 98 13.5
150 160 141 214 200 220 130 80 140 70 140 90 130 122 120
154 155 212 222 226 299 130 80 138 84 128 86 140 90 68 17.3
150 120 128 190 182 142 160 100 150 90 150 90 114 128 131 39.7
128 156 139 6.4
130 125 115 0.5
176 156 139 232 180 162 120 112 103 6.8
179 217 397 275 251 607 110 93 89 26.4
167 151 118 350 253 133 150 100 140 80 110 70 140 104 78 27.1
0.5
1.4
5
180 156 152 290 299 238 140 100 130 80 120 76 150 138 121 18.9
110 79 89 5.4
1.7
127 110 107 0.7
140 130 121 16.2
103 114 123 175 105 148 120 70 130 80 120 70 93 70 85 18.9
148 129 110 188 202 140 140 80 130 78 130 84 163 111 101
3
9.7
155 140 163 198 200 228 123 139 118 10.9
144 96 98 227 189 263 76 75 91 17.3
150 100 140 90 140 90 140 121 131 15.8
150 100 160 100 160 90 3.6
150 90 140 80 130 90 8
110 130 217 11.3
130 126 57 5.5
236 180 204 310 260 222 150 90 140 90 140 80 110 100 77 16.8
130 120 105 170 160 156 142 122 111 12.7
242 210 205 408 300 323 140 88 130 90 130 90 172 140 152 10.5
120 116 110 156 136 180 150 88 140 90 140 80 176 110 99 14.8
127 246 166 366 159 303 140 90 150 94 130 84 150 120 99 13.6
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ANNEXURE 8-STANDARD CRITERIA USED FOR DIAGNOSIS OF DISEASES OF 
INTEREST AND TREATMENT TARGETS. 
 
TYPE2 DIABETES MELLITUS 
American Diabetic association 2015 guidelines 
 
A1C ≥6.5%* 
(Performed in lab using NGSP-certified method and standardized to DCCT assay ) 
 
FPG ≥126 mg/dL (7.0 mmol/L)* 
Fasting defined as no caloric intake for ≥8 hrs  
 
2-hr PG ≥200 mg/dL (11.1 mmol/L) during OGTT (75-g)*  
Performed as described by the WHO, using glucose load containing the equlivalent of 
75g anhydrous glucose dissolved in water 
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Random PG ≥200 mg/dL (11.1 mmol/L) 
In persons with symptoms of hyperglycemia or hyperglycemic crisis  
 
 
*In the absence of unequivocal hyperglycemia results should be confirmed using repeat 
testing 
 
TREATMENT GOALS 
 
HbA1c <  7 in non pregnant adults. 
 
Or < 6.5 in pregnancy or Type 1 diabetes 
 
Fasting plasma glucose less than 126mg/dl 
Post prandial plasma glucose less than 180mg/dl 
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SYSTEMIC HYPERTENSION 
JNC 8 Guidelines for diagnosis  
 
Age ≥60 SBP ≥150 mm Hg  
or  
DBP ≥90 mm Hg 
 
 
Age ≤60 DBP ≥90 mm Hg 
SBP ≥140 mm Hg 
Age ≥18 with CKD† SBP ≥140 mm Hg  
or  
DBP ≥90 mm Hg 
Age ≥18 with diabetes SBP ≥140 mm Hg  
or  
DBP ≥90 mm Hg 
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Treatment goals would be to maintain blood pressures below the abovementioned levels. 
 
DYSLIPIDEMIA 
NCEP ATP III GUIDELINES- DIAGNOSIS AND TREATMENT GOALS 
 LDL Cholesterol - Primary Target of Therapy 
<100 Optimal 
100-129 Near Optimal/Above Optimal 
130-159 Borderline High 
160-189 High 
 
190 
Very high 
 Total Cholesterol 
<200 Desirable 
200-239 Borderline High 
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240 
High 
 HDL Cholesterol 
<40 Low 
>60 
 
High 
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CHRONIC KIDNEY DISEASE 
 Revised chronic kidney disease classification based upon glomerular filtration rate and 
albuminuria 
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GFR stages  
GFR   (mL/min/1.73 m2)  
G1 >90 Normal or high 
G2 60 to 89 Mildly decreased 
G3a 45 to 59 Mildly to moderately decreased 
G3b 30 to 44 Moderately to severely decreased 
G4 15 to 29 Severely decreased 
G5 <15 Kidney failure (add D if treated by dialysis) 
 
Albuminuria stages  
AER  (mg/day) Terms 
A1 <30            Normal to mildly increased (may be subdivided for risk prediction) 
A2 30 to 300 Moderately increased 
A3 >300             Severely increased (may be subdivided into nephrotic and non-               
nephrotic for differential diagnosis, management, and risk prediction) 
 132 
 
 
 
GFR: glomerular filtration rate; AER: albumin excretion rate; CKD: chronic kidney 
disease; KDIGO: Kidney Disease Improving Global Outcomes. 
Data from: 
1. KDIGO. Summary of recommendation statements. Kidney Int 2013; 3 (Suppl):5. 
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic 
kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 
(Suppl 1):S1. 
 
OSTEOPOROSIS 
 
Test Results using DEXA                         Interpretation(WHO) 
                                    
 
T-score -2.5 and lower                              Osteoporosis 
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 T-score between -1 and -2.5                     Osteopenia 
 
T-score -1 and higher                                 Normal  
 
 
Z-score -2.0 and lower                      Below expected range for age  
 
 
Z-score above -2.0                            Within expected range for age  
 
 
Bone density - assessed by dual energy X-ray absorptiometry (DEXA) 
 
ISCHAEMIC HEART DISEASE 
ECG changes suggestive of ischaemia and/or treadmill test positivity in patients who are 
symptomatic or have ECG changes. 
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CEREBROVASCULAR DISEASE 
Previous history of the same or evidence in the form of residual deficits or previous 
imaging will be considered 
 
LIPODYSTROPHY 
 
Trunk fat/lower limb fat mass ratio >2.28 identified 54.3% of patients with HIV 
receiving HAART as having lipodystrophy and had the highest odds ratio for predicting 
metabolic syndrome; based on a previous study conducted in our institution which 
developed an objective definition of HIV associated lipodystrophy using regional fat 
mass ratios.(75) 
Hence trunk fat/lower limb fat mass ratio more than 2.28 is taken as  as cut off for 
defining lipodystrophy..  
 
METABOLIC SYNDROME-NCEP ATP III GUIDELINES 
Any three (or more) of the following factors constitute a diagnosis of metabolic 
syndrome: 
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 Increased waist circumference: ethnicity specific - eg, Caucasian men ≥94 cm and 
women ≥80 cm; South Asian men ≥90 cm and women ≥80 cm. 
 If body mass index is over 30 kg/m
2
, central obesity can be assumed and waist 
circumference does not need to be measured. 
 Raised triglycerides: 
o >150 mg/dL (1·7 mmol/L) 
o Or specific treatment for this lipid abnormality 
 Reduced HDL-cholesterol: 
o <40 mg/dL (1·03 mmol/L) in men 
o <50 mg/dL (1·29 mmol/L) in women 
o Or specific treatment for this lipid abnormality 
 Raised blood pressure: 
o Systolic ≥130 mm Hg 
o Diastolic ≥85 mm Hg 
o Or treatment of previously diagnosed hypertension 
 Raised fasting plasma glucose: 
o Fasting plasma glucose ≥100 mg/dL (5·6 mmol/L) 
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Central obesity( WHO classification for Asians): 
 
    Waist circumference >= 90cm in men and >=80cm in women. 
 
 
 General obesity ( WHO classification for Asia-Pacific region): 
 
1. Under weight: BMI <18.5Kg/M² 
2. Normal: BMI 18.5 to 22.9Kg/M² 
3. Overweight: BMI 23 to 24.9Kg/M² 
4. Obese class I: BMI 25 to 29.9Kg/M² 
5. Obese class II:BMI ≥ 30Kg/M² 
 
(Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes 
Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood 
Institute; American Heart Association; World Heart Federation; International Atherosclerosis 
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Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 
20;120(16):1640-5.) 
 
 
SMOKING STATUS  
(Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N, et al. Cigarette Smoking and 
Fat Distribution in 21, 828 British Men and Women: A Population-based Study. Obes Res. 
2005 Aug 1; 13(8):1466–75. ) 
 
a) Current smokers: Smoking at present. 
 
b) Former smokers : Not smoking at present but had previously smoked one 
cigarette a day for atleast  a year 
 
c) Never smokers: Smoked neither at present nor in the past. 
 
One smoking pack year will be equivalent to one cigarette pack per day for one year. 
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ALCOHOL CONSUMPTION  
( Dorn JM, Hovey K, Muti P, Freudenheim JL, Russell M, Nochajski TH, et al. Alcohol 
Drinking Patterns Differentially Affect Central Adiposity as Measured by Abdominal Height 
in Women and Men. J Nutr. 2003 Aug 1;133(8):2655–62, Schroder et al : The relationship 
between waist- to-hip ratio and occupational status and life-style factors among middle aged 
male and female Japanese workers) 
 
(a) Lifetime abstainer: Never had 12 or more drinks in their lifetime or in any 1 year 
period. 
 
(b) Noncurrent drinker: Previously consumed 12 or more drinks in their lifetime or in 
any one-year period, but did not consume any alcohol in the previous 30 days. 
 
(c) Current drinker: Consumed at least one alcoholic beverage in the 30 days before the 
interview. 
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Alcohol intake in grams will be calculated by multiplying the amount of beverage 
consumed in milliliters with the grade (percentage) of alcohol and the constant 0.80 to 
transform alcohol volumes into weight. 11% for wine, 5% for beer and 40% for spirits 
are the defined grades.
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